KRAS and pancreatic neoplasm: Unlike in NSCLC, G12C mutations represent only a minor fraction of KRAS mutations detected in PDAC, yet this therapeutic approach has been evaluated in gastrointestinal carcinomas including pancreatic cancer, albeit with limited success.